Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.

  title={Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.},
  author={Mehmet Faruk Kose and Mehmet Mutlu Meydanli and G{\"o}khan Tulunay},
  journal={Expert review of anticancer therapy},
  volume={6 3},
Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the time from first relapse of their disease to death will be longer than the period from diagnosis to that first relapse. There is current evidence from prospective randomized trials… CONTINUE READING